(Corrects second paragraph to show muscle relaxants already marketed n the U.S.)

Jan. 2 (Bloomberg) -- Schering-Plough Corp.'s experimental drug for undoing the effects of muscle relaxants used during surgery will get priority review from U.S. regulators.

The drug, sugammadex, reverses the effects of muscle relaxants marketed in the U.S. as Zemuron and vecuronium bromide, according to a statement on PR Newswire today. Schering acquired sugammadex as part of its March purchase of Akzo Nobel NV's Organon division. A priority review by the U.S. Food and Drug Administration reduces the approval process to six months from at least 10.

To contact the reporter on this story: Beth Jinks in New York at bjinks1@bloomberg.net

Last Updated: January 2, 2008 17:36 EST